With Clintest Voice we are able to rapidly create test scripts and automate many aspects of our IVR testing in an environment where time is money.
San Francisco, California (PRWEB) December 08, 2011
Today, endpoint (http://www.endpointclinical.com) announced a partnership with RealityCorp to trial their product Clintest Voice. Clintest Voice offers clients a dynamic, easy to use solution for IVR test automation in a fast-paced, ever-changing industry.
“With Clintest Voice we are able to rapidly create test scripts and automate many aspects of our IVR testing in an environment where time is money. The adoption of Clintest allows us to further leverage the rapid development of the endpoint PULSE product.” said Jonathan Ball, Testing Manager at endpoint.
The introduction of eClinical automation software is rapidly approaching, and after thorough due diligence, endpoint believes they have found a feasible solution to advance technology, accurately and safely. With the demanding deadlines and multitude of changes from study to study, preparation of automation scripts has always been a challenge for IVR systems; however, RealityCorp’s ClinTest Voice offers endpoint a rapidly configurable way to create test scripts in an exceptionally user friendly product. The expectation is that endpoint will be able to save several days in testing and will be able to create a more consistent and bug free product.
RealityCorp’s Clintest Voice has made automated testing possible within the Clinical Trial space by:
- Allowing test engineers to create easy to use, configurable test scripts.
- Offering the testing team the option to never have to dial into the IVR again.
- Producing accurate, relevant testing objective evidence that is comprehendible at any level.
endpoint is an innovative company dedicated to the development of the leading Integrated Voice Response (IVR/IWR) technology platforms for the life sciences industry. endpoint’s founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.